In Brief: Bard's Telescope
This article was originally published in The Gray Sheet
Bard's Telescope: Single-operator, over-the-wire balloon catheter is approved by FDA for use in coronary angioplasty. The company says it plans a domestic launch of the product in early 1998 and outside the U.S. "when production volumes permit." Components in the device shaft facilitate length adjustment of the catheter while "anti-backbleed" and "wirelock" features help prevent blood loss during angioplasty procedures, Bard claims...
You may also be interested in...
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.
With Warp Speed Decisions Already Made, Transitioning To Biden Admin Should Be No Trouble, Slaoui Says
As vaccines near availability, Moncef Slaoui says his full-time role at OWS may be ending. He has not met with the Biden Transition team, but notes that other Warp Speed officials have.
Strong top-line efficacy in pyruvate kinase deficiency patients who don’t receive regular transfusions looks approvable, analysts say, but Agios will await data in regularly transfused patients.